Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.870
-0.030 (-1.58%)
Aug 5, 2026, 12:37 PM EDT - Market open

Silexion Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-12.91-11.91-16.52-5.11-3.49
Depreciation & Amortization
0.010.010.030.050.06
Stock-Based Compensation
0.460.135.860.130.13
Other Adjustments
0.270.343.820.32-0.27
Change in Receivables
-0.05----0.04
Changes in Accounts Payable
0.19-0.140.610.08-0.04
Changes in Accrued Expenses
-0.080.240.440.31-0.06
Changes in Other Operating Activities
-0.050.51-2.63-0.310.38
Operating Cash Flow
-12.01-10.82-8.4-4.53-3.34
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Capital Expenditures
-0-0.01-0.02-0.01-0.04
Sale of Property, Plant & Equipment
---0.08-
Purchases of Investments
--0.01---0.5
Proceeds from Sale of Investments
---0.510.02
Investing Cash Flow
-0.01-0.01-0.020.57-0.52

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Long-Term Debt Repaid
--0.7-0.25--
Net Long-Term Debt Issued (Repaid)
--0.7-0.25--
Issuance of Common Stock
9.6218.685.35-0
Net Common Stock Issued (Repurchased)
9.6218.685.35-0
Issuance of Preferred Stock
---0.522.75
Net Preferred Stock Issued (Repurchased)
---0.522.75
Other Financing Activities
-1.26-2.34---
Financing Cash Flow
8.2915.645.10.522.75

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Foreign Exchange Rate Adjustments
-0.01-0-0.06-0.23-0.67
Net Cash Flow
-3.734.81-3.31-3.43-1.11

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-12.02-10.83-8.42-4.54-3.38
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-59.41-81.44---
Levered Free Cash Flow
-10.1-12-18.27-4.82-2.92
Unlevered Free Cash Flow
-9.91-11.03-14.16-4.59-3.59
SEC Filings: 10-K · 10-Q